Scilex Holding Company has announced an update to its merger agreement involving its wholly owned subsidiary, Semnur Pharmaceuticals, Inc., and Denali Capital Acquisition Corp. An amendment, known as Amendment No. 2, has been made to the original merger agreement. This amendment modifies the definitions of "Exchange Ratio" and "Merger Consideration," allowing for the issuance of additional shares of Semnur's common stock prior to the closing of the merger. These shares may be used in connection with potential private placement financing or issued to advisors and service providers. The exchange ratio will be maintained at 1.25-to-1.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scilex Holding Company published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-162969), on July 23, 2025, and is solely responsible for the information contained therein.